{"success":true,"data":{"pressRelease":{"id":"130716","rtpr_id":"nPn1HvWqka","ticker":"1672","exchange":"HKEX","all_tickers":["1672"],"title":"Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management","author":"PR Newswire","published_at":"2026-08-30T10:15:00.427Z","article_body":"Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management\n\nPR Newswire\n\nHONG KONG, Aug. 30, 2026\n\n- Expected to enroll approximately 4,600 participants with obesity or\noverweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S.,\nEurope, and Canada.\n\n- Global Phase III clinical program to investigate efficacy and safety of\nthree maintenance doses (20 mg, 40 mg, and 60 mg) over 72 weeks in\nparticipants with obesity or overweight without type 2 diabetes (AURORA-1) and\nwith type 2 diabetes (AURORA-2).\n\n- Topline data from the AURORA Phase III clinical program are expected in the\nthird quarter of 2028, with a U.S. Food and Drug Administration (FDA) New Drug\nApplication (NDA) submission expected by the end of 2028 and European\nMedicines Agency (EMA) Marketing Authorisation Application (MAA) submission\nexpected in early 2029.\n\n- ASC30 has the potential to become the second oral small molecule GLP-1\nreceptor agonist available in the U.S. and Europe, if approved.\n\nHONG KONG, Aug. 30, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,\n\"Ascletis\") announced that the first participant has been dosed in a global\nPhase III clinical program of ASC30 for chronic weight management. ASC30 is an\ninvestigational, proprietary once-daily oral small molecule glucagon-like\npeptide-1 receptor (GLP-1R) agonist being developed for chronic weight\nmanagement and diabetes.\n\nThe global Phase III clinical program consists of two pivotal, multicenter,\nrandomized, double-blind, placebo-controlled Phase III trials, AURORA-1\n(NCT07743463\n(https://clinicaltrials.gov/study/NCT07743463?cond=NCT07743463&viewType=Card&rank=1)\n) and AURORA-2 (NCT07743450\n(https://clinicaltrials.gov/study/NCT07743450?cond=NCT07743450&viewType=Card&rank=1)\n), evaluating the long-term efficacy, safety, and tolerability of ASC30\nonce-daily oral tablets in approximately 4,600 participants across clinical\nsites in the U.S., Europe, and Canada.\n\n\"Obesity is a complex, chronic disease associated with over 200 comorbidities\nand represents an immense global public health burden. While injectable\nincretin therapies have transformed obesity care, there remains substantial\nunmet need for an oral small molecule that is effective, well-tolerated, and\nconvenient enough to expand patient access and support long-term adherence.\"\nsaid Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, \"Dosing the\nfirst participant in our AURORA global Phase III clinical program marks a\ntransformative milestone for Ascletis. ASC30 enters this pivotal stage backed\nby a competitive Phase II weight loss profile, favorable gastrointestinal\ntolerability, and no observed hepatic safety signals. We believe this\nfoundation supports ASC30's potential as a category-leading oral therapy, with\nthe goal of bringing patients a once-daily oral GLP-1 option approved\nglobally.\"\n\nAscletis expects to report topline data from the AURORA Phase III clinical\nprogram in the third quarter of 2028. The Company expects to submit a New Drug\nApplication (NDA) to the U.S. Food and Drug Administration (FDA) by the end of\n2028 and a Marketing Authorisation Application (MAA) to the European Medicines\nAgency (EMA) in early 2029. Ascletis maintains a strong balance sheet with\nsufficient cash on hand to support operations into 2029, fully funding the\nprogram beyond the planned U.S. and European regulatory submissions.\n\nAscletis has one of the most comprehensive and leading oral small molecule\nportfolios for obesity. In addition to the AURORA global Phase III monotherapy\nprogram, Ascletis is also developing the first tirzepatide-like oral small\nmolecule dual agonist fixed-dose combination GLP-1/GIP (ASC30_48FDC), the\nfirst tirzepatide/eloralintide-like oral small molecule triple agonist\nfixed-dose combination GLP-1/GIP/amylin (ASC30_48_39FDC), and a fixed-dose\ncombination of our small molecule oral GLP-1 and oral amylin (ASC30_39FDC).\n\nAbout the ASC30 Global Phase III Clinical Program\n\nThe ASC30 global Phase III clinical program consists of two pivotal,\nmulticenter, randomized, double-blind, placebo-controlled Phase III trials,\nAURORA-1 (NCT07743463\n(https://clinicaltrials.gov/study/NCT07743463?cond=NCT07743463&viewType=Card&rank=1)\n) and AURORA-2 (NCT07743450\n(https://clinicaltrials.gov/study/NCT07743450?cond=NCT07743450&viewType=Card&rank=1)\n), which are designed to evaluate the long-term efficacy, safety, and\ntolerability of once-daily oral ASC30 compared to placebo in approximately\n4,600 adults living with obesity or overweight, with treatment duration of 72\nweeks and across both pivotal trials:\n\nAURORA-1 (NCT07743463\n(https://clinicaltrials.gov/study/NCT07743463?cond=NCT07743463&viewType=Card&rank=1)\n): A pivotal trial evaluating efficacy and safety of once-daily oral ASC30 in\nparticipants with obesity (body mass index (BMI) ≥ 30 kg/m(2)) or overweight\n(BMI ≥ 27 kg/m(2) with at least one weight-related comorbidity), excluding\ntype 2 diabetes. Participants are randomized to one of three maintenance doses\nof ASC30 (20 mg, 40 mg, or 60 mg) or placebo. The primary endpoint is the\npercentage change in body weight from baseline to Week 72.\n\nAURORA-2 (NCT07743450\n(https://clinicaltrials.gov/study/NCT07743450?cond=NCT07743450&viewType=Card&rank=1)\n): A pivotal trial evaluating efficacy and safety of once-daily oral ASC30 in\nparticipants with obesity or overweight (BMI ≥ 27 kg/m(2)) and with type 2\ndiabetes. Participants are randomized to one of three maintenance doses of\nASC30 (20 mg, 40 mg, or 60 mg), or placebo. The primary endpoint is the\npercentage change in body weight from baseline to Week 72.\n\nAbout ASC30\n\nASC30 was discovered and developed in-house by Ascletis as an investigational\noral small molecule GLP-1R fully biased agonist. It serves as the primary\npillar of Ascletis' comprehensive, industry-leading oral small molecule\nobesity portfolio, which also includes fixed-dose combinations spanning GLP-1,\nGIP, and amylin targets (such as ASC30_48FDC, ASC30_48_39FDC and ASC30_39FDC)\nto provide convenient, one-pill, once-daily treatment options for people\nliving with obesity and other metabolic diseases.\n\nAbout Ascletis Pharma Inc.\n\nAscletis Pharma Inc. is a fully integrated biotechnology company focused on\nthe development and commercialization of potentially best-in-class and\nfirst-in-class therapeutics to treat metabolic diseases. Utilizing its\nproprietary Artificial Intelligence-assisted Structure-Based Drug Discovery\n(AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide\nOral Transport ENhancement Technology (POTENT), Ascletis has developed\nmultiple drug candidates in-house, including both small molecules and\npeptides, such as its lead program, ASC30, a once-daily oral small molecule\nGLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a\nonce-daily oral small molecule dual agonist, a fixed dose combination of ASC30\n(GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral\nsmall molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R\nagonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)),\nASC39, an eloralintide-like potent selective amylin receptor agonist (SARA)\nonce-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule\ndual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39\n(amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be\nadministered once monthly to once quarterly subcutaneously and once daily\norally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual\npeptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide\nagonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35\n(GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist,\ndesigned to be administered once monthly subcutaneously and once daily orally,\nand ASC36_37FDC, a once-monthly subcutaneous quadruple peptide agonist, a\nfixed dose combination of ASC36 (amylin receptor agonist) and ASC37\n(GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed\non the Hong Kong Stock Exchange (1672.HK).\n\nFor more information, please visit www.ascletis.com\n(https://www.ascletis.com/) .\n\nContact:\n\nPeter Vozzo\nICR Healthcare\n443-231-0505 (U.S.)\nPeter.vozzo@icrhealthcare.com (mailto:Peter.vozzo@icrhealthcare.com)\n\nAscletis Pharma Inc. PR and IR Teams\n+86-181-0650-9129 (China)\npr@ascletis.com (mailto:pr@ascletis.com)\nir@ascletis.com (mailto:ir@ascletis.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ascletis-announces-first-participant-dosed-in-a-global-phase-iii-clinical-program-of-once-daily-oral-small-molecule-glp-1-receptor-agonist-asc30-for-chronic-weight-management-302864376.html\n(https://www.prnewswire.com/news-releases/ascletis-announces-first-participant-dosed-in-a-global-phase-iii-clinical-program-of-once-daily-oral-small-molecule-glp-1-receptor-agonist-asc30-for-chronic-weight-management-302864376.html)\n\nSOURCE Ascletis Pharma Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1810014/Ascletis-Pharma-Logo.jpg?id=OA2919156\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1HvWqka","title":"Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management","author":"PR Newswire","ticker":"1672","created":"2026-08-30T10:15:00.427Z","tickers":["1672"],"exchange":"HKEX","article_body":"Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management\n\nPR Newswire\n\nHONG KONG, Aug. 30, 2026\n\n- Expected to enroll approximately 4,600 participants with obesity or\noverweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S.,\nEurope, and Canada.\n\n- Global Phase III clinical program to investigate efficacy and safety of\nthree maintenance doses (20 mg, 40 mg, and 60 mg) over 72 weeks in\nparticipants with obesity or overweight without type 2 diabetes (AURORA-1) and\nwith type 2 diabetes (AURORA-2).\n\n- Topline data from the AURORA Phase III clinical program are expected in the\nthird quarter of 2028, with a U.S. Food and Drug Administration (FDA) New Drug\nApplication (NDA) submission expected by the end of 2028 and European\nMedicines Agency (EMA) Marketing Authorisation Application (MAA) submission\nexpected in early 2029.\n\n- ASC30 has the potential to become the second oral small molecule GLP-1\nreceptor agonist available in the U.S. and Europe, if approved.\n\nHONG KONG, Aug. 30, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,\n\"Ascletis\") announced that the first participant has been dosed in a global\nPhase III clinical program of ASC30 for chronic weight management. ASC30 is an\ninvestigational, proprietary once-daily oral small molecule glucagon-like\npeptide-1 receptor (GLP-1R) agonist being developed for chronic weight\nmanagement and diabetes.\n\nThe global Phase III clinical program consists of two pivotal, multicenter,\nrandomized, double-blind, placebo-controlled Phase III trials, AURORA-1\n(NCT07743463\n(https://clinicaltrials.gov/study/NCT07743463?cond=NCT07743463&viewType=Card&rank=1)\n) and AURORA-2 (NCT07743450\n(https://clinicaltrials.gov/study/NCT07743450?cond=NCT07743450&viewType=Card&rank=1)\n), evaluating the long-term efficacy, safety, and tolerability of ASC30\nonce-daily oral tablets in approximately 4,600 participants across clinical\nsites in the U.S., Europe, and Canada.\n\n\"Obesity is a complex, chronic disease associated with over 200 comorbidities\nand represents an immense global public health burden. While injectable\nincretin therapies have transformed obesity care, there remains substantial\nunmet need for an oral small molecule that is effective, well-tolerated, and\nconvenient enough to expand patient access and support long-term adherence.\"\nsaid Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, \"Dosing the\nfirst participant in our AURORA global Phase III clinical program marks a\ntransformative milestone for Ascletis. ASC30 enters this pivotal stage backed\nby a competitive Phase II weight loss profile, favorable gastrointestinal\ntolerability, and no observed hepatic safety signals. We believe this\nfoundation supports ASC30's potential as a category-leading oral therapy, with\nthe goal of bringing patients a once-daily oral GLP-1 option approved\nglobally.\"\n\nAscletis expects to report topline data from the AURORA Phase III clinical\nprogram in the third quarter of 2028. The Company expects to submit a New Drug\nApplication (NDA) to the U.S. Food and Drug Administration (FDA) by the end of\n2028 and a Marketing Authorisation Application (MAA) to the European Medicines\nAgency (EMA) in early 2029. Ascletis maintains a strong balance sheet with\nsufficient cash on hand to support operations into 2029, fully funding the\nprogram beyond the planned U.S. and European regulatory submissions.\n\nAscletis has one of the most comprehensive and leading oral small molecule\nportfolios for obesity. In addition to the AURORA global Phase III monotherapy\nprogram, Ascletis is also developing the first tirzepatide-like oral small\nmolecule dual agonist fixed-dose combination GLP-1/GIP (ASC30_48FDC), the\nfirst tirzepatide/eloralintide-like oral small molecule triple agonist\nfixed-dose combination GLP-1/GIP/amylin (ASC30_48_39FDC), and a fixed-dose\ncombination of our small molecule oral GLP-1 and oral amylin (ASC30_39FDC).\n\nAbout the ASC30 Global Phase III Clinical Program\n\nThe ASC30 global Phase III clinical program consists of two pivotal,\nmulticenter, randomized, double-blind, placebo-controlled Phase III trials,\nAURORA-1 (NCT07743463\n(https://clinicaltrials.gov/study/NCT07743463?cond=NCT07743463&viewType=Card&rank=1)\n) and AURORA-2 (NCT07743450\n(https://clinicaltrials.gov/study/NCT07743450?cond=NCT07743450&viewType=Card&rank=1)\n), which are designed to evaluate the long-term efficacy, safety, and\ntolerability of once-daily oral ASC30 compared to placebo in approximately\n4,600 adults living with obesity or overweight, with treatment duration of 72\nweeks and across both pivotal trials:\n\nAURORA-1 (NCT07743463\n(https://clinicaltrials.gov/study/NCT07743463?cond=NCT07743463&viewType=Card&rank=1)\n): A pivotal trial evaluating efficacy and safety of once-daily oral ASC30 in\nparticipants with obesity (body mass index (BMI) ≥ 30 kg/m(2)) or overweight\n(BMI ≥ 27 kg/m(2) with at least one weight-related comorbidity), excluding\ntype 2 diabetes. Participants are randomized to one of three maintenance doses\nof ASC30 (20 mg, 40 mg, or 60 mg) or placebo. The primary endpoint is the\npercentage change in body weight from baseline to Week 72.\n\nAURORA-2 (NCT07743450\n(https://clinicaltrials.gov/study/NCT07743450?cond=NCT07743450&viewType=Card&rank=1)\n): A pivotal trial evaluating efficacy and safety of once-daily oral ASC30 in\nparticipants with obesity or overweight (BMI ≥ 27 kg/m(2)) and with type 2\ndiabetes. Participants are randomized to one of three maintenance doses of\nASC30 (20 mg, 40 mg, or 60 mg), or placebo. The primary endpoint is the\npercentage change in body weight from baseline to Week 72.\n\nAbout ASC30\n\nASC30 was discovered and developed in-house by Ascletis as an investigational\noral small molecule GLP-1R fully biased agonist. It serves as the primary\npillar of Ascletis' comprehensive, industry-leading oral small molecule\nobesity portfolio, which also includes fixed-dose combinations spanning GLP-1,\nGIP, and amylin targets (such as ASC30_48FDC, ASC30_48_39FDC and ASC30_39FDC)\nto provide convenient, one-pill, once-daily treatment options for people\nliving with obesity and other metabolic diseases.\n\nAbout Ascletis Pharma Inc.\n\nAscletis Pharma Inc. is a fully integrated biotechnology company focused on\nthe development and commercialization of potentially best-in-class and\nfirst-in-class therapeutics to treat metabolic diseases. Utilizing its\nproprietary Artificial Intelligence-assisted Structure-Based Drug Discovery\n(AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide\nOral Transport ENhancement Technology (POTENT), Ascletis has developed\nmultiple drug candidates in-house, including both small molecules and\npeptides, such as its lead program, ASC30, a once-daily oral small molecule\nGLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a\nonce-daily oral small molecule dual agonist, a fixed dose combination of ASC30\n(GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral\nsmall molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R\nagonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)),\nASC39, an eloralintide-like potent selective amylin receptor agonist (SARA)\nonce-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule\ndual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39\n(amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be\nadministered once monthly to once quarterly subcutaneously and once daily\norally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual\npeptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide\nagonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35\n(GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist,\ndesigned to be administered once monthly subcutaneously and once daily orally,\nand ASC36_37FDC, a once-monthly subcutaneous quadruple peptide agonist, a\nfixed dose combination of ASC36 (amylin receptor agonist) and ASC37\n(GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed\non the Hong Kong Stock Exchange (1672.HK).\n\nFor more information, please visit www.ascletis.com\n(https://www.ascletis.com/) .\n\nContact:\n\nPeter Vozzo\nICR Healthcare\n443-231-0505 (U.S.)\nPeter.vozzo@icrhealthcare.com (mailto:Peter.vozzo@icrhealthcare.com)\n\nAscletis Pharma Inc. PR and IR Teams\n+86-181-0650-9129 (China)\npr@ascletis.com (mailto:pr@ascletis.com)\nir@ascletis.com (mailto:ir@ascletis.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ascletis-announces-first-participant-dosed-in-a-global-phase-iii-clinical-program-of-once-daily-oral-small-molecule-glp-1-receptor-agonist-asc30-for-chronic-weight-management-302864376.html\n(https://www.prnewswire.com/news-releases/ascletis-announces-first-participant-dosed-in-a-global-phase-iii-clinical-program-of-once-daily-oral-small-molecule-glp-1-receptor-agonist-asc30-for-chronic-weight-management-302864376.html)\n\nSOURCE Ascletis Pharma Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1810014/Ascletis-Pharma-Logo.jpg?id=OA2919156\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-30T10:15:00.470133665Z","server_sent_at_ms":1788084900470},"received_at":"2026-08-30T10:15:00.788Z","source_url":"https://www.prnewswire.com/news-releases/ascletis-announces-first-participant-dosed-in-a-global-phase-iii-clinical-program-of-once-daily-oral-small-molecule-glp-1-receptor-agonist-asc30-for-chronic-weight-management-302864376.html"},"analysis":{"id":"119625","press_release_id":"130716","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Ascletis dosed the first participant in a global Phase III program for ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management.\n\nThe AURORA program comprises two pivotal trials (AURORA-1 and AURORA-2) targeting approximately 4,600 patients with obesity or overweight, with topline data expected in Q3 2028.\n\nManagement noted sufficient cash to fund operations into 2029, covering the planned FDA NDA submission by end of 2028 and EMA MAA submission in early 2029.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Phase III initiation for oral GLP-1 asset ASC30 positions Ascletis in the competitive obesity market with data due in 2028."},"keyFigures":{"drugName":"ASC30","phaseOfTrial":"Phase III","customDimensions":{"trial_enrollment":4600,"maintenance_doses_mg":[20,40,60],"treatment_duration_weeks":72}},"quotedText":"Dosing the first participant in our AURORA global Phase III clinical program marks a transformative milestone for Ascletis.","namedEntities":{"people":[{"name":"Jinzi Jason Wu","role":"Founder, Chairman and CEO"},{"name":"Peter Vozzo","role":"Contact (ICR Healthcare)"}],"products":["ASC30","ASC30_48FDC","ASC30_48_39FDC","ASC30_39FDC","ASC36","ASC35","ASC36_35FDC","ASC37","ASC36_37FDC","ASC39","ASC48"],"companies":[{"name":"Ascletis Pharma Inc.","ticker":"1672"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"European Medicines Agency","relationship":"regulator"},{"name":"ICR Healthcare","relationship":"PR/IR firm"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Initiation of a global Phase III program (AURORA-1 and AURORA-2) for a lead asset in the high-visibility obesity/GLP-1 market. The 4,600-patient study design and 2028 data timeline represent a de-risking and value-inflection milestone."},"tickerRelevance":{"others":[],"primary":"1672"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"phase_3_initiation_lead_asset","sectorWeight":"biotech_high_interest","marketCapAdjustment":"non_us_listed_hkex"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Ascletis dosed the first participant in a global Phase III program for ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management.\n\nThe AURORA program comprises two pivotal trials (AURORA-1 and AURORA-2) targeting approximately 4,600 patients with obesity or overweight, with topline data expected in Q3 2028.\n\nManagement noted sufficient cash to fund operations into 2029, covering the planned FDA NDA submission by end of 2028 and EMA MAA submission in early 2029.","key_figures":{"drugName":"ASC30","phaseOfTrial":"Phase III","customDimensions":{"trial_enrollment":4600,"maintenance_doses_mg":[20,40,60],"treatment_duration_weeks":72}},"named_entities":{"people":[{"name":"Jinzi Jason Wu","role":"Founder, Chairman and CEO"},{"name":"Peter Vozzo","role":"Contact (ICR Healthcare)"}],"products":["ASC30","ASC30_48FDC","ASC30_48_39FDC","ASC30_39FDC","ASC36","ASC35","ASC36_35FDC","ASC37","ASC36_37FDC","ASC39","ASC48"],"companies":[{"name":"Ascletis Pharma Inc.","ticker":"1672"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"European Medicines Agency","relationship":"regulator"},{"name":"ICR Healthcare","relationship":"PR/IR firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-30T10:15:33.225Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"phase_3_initiation_lead_asset","sectorWeight":"biotech_high_interest","marketCapAdjustment":"non_us_listed_hkex"}},"durationMs":32427,"modelName":"glm-4.7"}}